Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition

American Heart Journal

Volumn 135, Issue 4, 1998, Pages

  Ferguson, J J ^a   Waly, H M ^a   Wilson, J M ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; EFEGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; HEPTAPEPTIDE; HIRUDIN; HIRULOG; INOGATRAN; LAMIFIBAN; ORBOFIBAN; SIBRAFIBAN; THROMBIN; THROMBIN INHIBITOR; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANTICOAGULATION; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031970983     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70296-0     Document Type: Article

References (51)

1. E Falk PK Shah V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
2. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
3. Y. Nemerson Sequence of coagulation reactions 4th ed WJ Williams E Bentler AJ Erstev MA Lichtman Hematology. 1990 McGraw-Hill New York: 1295 1304
4. E Barasch JM Wilson JJ. Ferguson Anticoagulation and PTCA GL Freeman Developments in cardiology. 1994 W.B. Saunders Philadelphia 91 103
5. B Stein V Fuster JL Halperin JH. Chesebro Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk Circulation 80 1989 1501 1513
6. HR Roberts JN. Lozier New perspectives on the coagulation cascade Hosp Pract 27 1992 97 112
7. AI. Schafer Coagulation cascade: an overview J Loscalzo AI Schafer Thrombosis and hemorrhage. 1994 Blackwell Scientific Boston 3 12
8. J. Weitz New anticoagulant strategies: current status and future potential Drugs 48 1994 485 497
9. EJ. Topol Novel antithrombotic approaches to coronary artery disease Am J Cardiol 75 suppl B 1995 27B 33B
10. J Fuchs CP Cannon TIMI 7 Investigators Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial Circulation 92 1995 727 733
11. P Théroux F Pérez-Villa D Waters J Lespérance F Shabani R. Bonan Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction Circulation 91 1995 2132 2139
12. RC Becker CP. Cannon Hirudin: its biology and clinical use J Thrombosis Thrombolysis 1 1994 7 16
13. LV. Lee Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial Am J Cardiol 75 1995 7 13
14. CP Cannon E. Braunwald Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty J Am Coll Cardiol 25 suppl 1995 30S 37S
15. JA Bittl J Strony JA Brinker Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina N Engl J Med 333 1995 764 769
16. PW Serruys J-PR Herrman R Simon A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty N Engl J Med 333 1995 757 763
17. B. Kaiser Anticoagulant and antithrombotic actions of recombinant hirudin Semin Thrombosis Hemostasis 17 1991 130 135
18. EJ Topol R Bonan D Jewitt Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty Circulation 87 1993 1622 1629
19. J Lefkovits EJ. Topol Direct thrombin inhibitors in cardiovascular medicine Circulation 90 1994 1522 1536
20. Global Use of Strategies to Open Occluded Coronary Arteries GUSTO IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes Circulation 90 1994 1631 1637
21. JH Chesebro V. Fuster Dynamic thrombosis and thrombolysis: role of antithrombins Circulation 83 1991 1815 1817
22. K-L Neuhaus R Essen U Tebbe Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Circulation 90 1994 1638 1642
23. EM. Antman Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial Circulation 90 1994 1624 1630
24. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
25. EM. Antman Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation 94 1996 911 921
26. The Global Use of Strategies to Open Occluded Coronary Arteries GUSTO IIb Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes N Engl J Med 335 1996 775 782
27. LA Harker SR Hanson AB. Kelly Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation Thromb Haemost 78 1997 736 741
28. L Waxman DE Smith KE Arcuri GP. Vlasuk Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa Science 248 1990 593 596
29. TJ Girard LA MacPhail KM Likert WF Novotny JP Miletich GJ. Broze Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein Science 248 1990 1421 1424
30. J Lefkovits EJ. Topol Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease Eur Heart J 17 1996 9 18
31. J Lefkovits EF Plow EJ. Topol Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine N Engl J Med 332 1995 1553 1559
32. BS. Coller Blockade of platelet GPIIB/IIIa receptors as an antithrombotic strategy Circulation 92 1995 2373 2380
33. JR. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nature 231 1971 2352 2356
34. JW Burch N Stanford PW. Majerus Inhibition of platelet prostaglandin synthetase by oral aspirin J Clin Invest 61 1978 314 319
35. V Fuster I-K. Jang Role of platelet-inhibitor agents in coronary artery disease EJ Topol Textbook of interventional cardiology. 1994 W.B. Saunders Philadelphia 3 22
36. EA Jaffe BB. Weksler Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin J Clin Invest 63 1979 532 535
37. CAPRIE Steering Committee A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
38. BS Coller EI Peerschke LE Scudder CA. Sullivan A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa J Clin Invest 72 1983 325 338
39. IF Charo LS Bekeart DR. Phillips Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix J Biol Chem 262 1987 9935 9938
40. vβ3 AA Sasahara J Loscalzo New therapeutic agents in thrombosis and thrombolysis. 1997 Marcel Dekker New York 291 313
41. B Felding-Habermann DA. Cheresh Vitronectin and its receptors Curr Opin Cell Biol 5 1993 864 868
42. vβ3 integrin with a small peptide antagonist GpenGRGDSPCA J Vasc Surg 19 1994 125 134
43. EJ Topol RM Califf HF Weisman Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 343 1994 881 886
44. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
45. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
46. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 349 1997 1422 1428
47. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
48. White HD. PRISM. Presented at the 46th Annual Scientific Session of the American College of Cardiology; March 16-19, 1997, Anaheim, Calif.
49. Théroux P. PRISM-PLUS. Presented at the 46th Annual Scientific Session of the American College of Cardiology; March 16-19, 1997, Anaheim, Calif.
50. NS Kleiman EM Ohman RM Califf Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study J Am Coll Cardiol 22 1993 381 389
51. Califf RM. PURSUIT. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997, Stockholm, Sweden.